To include your compound in the COVID-19 Resource Center, submit it here.

Court sides with FDA in Sensipar exclusivity case

A federal court sided with FDA in a lawsuit in which Amgen Inc. (NASDAQ:AMGN) alleged that the agency had applied standards inconsistently when it denied pediatric exclusivity to Amgen's Sensipar

Read the full 305 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE